Home » March / April 2022 » Safety at the base of the choice of SIT (specific immunotherapy)
2022 | March / April 2022

Safety at the base of the choice of SIT (specific immunotherapy)

by cyb2025
F. Frati, F. Silvestri, A. Pisani, E. Compalati
Allergen Immunotherapy
allergoid
COVID-19
efficacy
PHARMACOVIGILANCE
safety

FRANCO FRATI, FRANCESCA SILVESTRI, ARIANNA PISANI, ENRICO COMPALATI
Lofarma S.p.A., Milan, Italy

ABSTRACT

Specific immunotherapy (SIT) is the first-choice treatment for allergic respiratory diseases. Over the years, the literature has demonstrated that the focus of specific allergen immunotherapy has always been on the search for a safe, easy to use treatment to ensure good patient compliance. The COVID-19 pandemic has severely put many treatment plans to the test but, in the immunotherapy sector, it has been and is still possible to adopt safe treatments that allow them to be continued even during the course of emergency vaccinations, like that of COVID-19.

SPECIFIC ALLERGEN IMMUNOTHERAPY FROM 1911 TO THE PRESENT DAY: PRIORITY TO SAFETY
Since its discovery in 1911 allergen-specific immunotherapy (AIT) has been widely used due to its efficacy and safety against allergic respiratory diseases.
The initial studies conducted on allergen-specific immunotherapy demonstrated its beneficial effect on hay fever and, in time, led to substantial scientific evidence, which has also been demonstrated by some meta-analyses (1).

ABOUT THE AUTHOR

Franco Frati – Expert in the pharmaceutical management at various levels of innovative scientific issues in the world of allergology applied to pulmonology, otolaryngology and pediatrics. Director of scientific teams won prestigious awards from the European Academy of allergy and clinical immunology.
In the top 10 scientists in scientific production activities in the field of allergen Immunotherapy.

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login